Phase 1 single and multiple ascending dose studies (NCT03976349) were conducted with the primary objective to evaluate the pharmacokinetics, safety, and tolerability of LRRK2 ASO BIIB094, delivered intrathecally to adult PD patients is ongoing. The gene discussed is LRRK2; the disease is Parkinson disease.